Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-07

Study Completion Date

2022-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to to verify the feasibility of obtaining and comparing two epithelia in two populations based on the following experiments:

* Differentiation of an Induced Pluripotent Stem cell (iPS) clone derived from cutaneous biopsy in a population of heavy smokers (plus patients with chronic obstructive pulmonary disease) in order to obtain differentiated bronchial epithelia in vitro.
* For each of these same patients, generation of bronchial epithelium in vitro from bronchial biopsy using human bronchial epithelial cells (HBECs) in air-liquid interface (ALI) cultures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

NCT07052396

Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING

IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study

NCT00883584

Chronic Obstructive Pulmonary Disease

UNKNOWN PHASE2

14729-D9831C00002- 1 Month Biopsy Study

NCT00766415

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

NCT04027439

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary objectives:

* Confrontation of the two models of in vitro generation of bronchial epithelium by iPS and ALI in order to validate our model of study of the human bronchial epithelium COPD generated by the iPS.
* Inducing a "COPD-like" epithelial phenotype by exposing the bronchial epithelia generated from the iPS to a source of in vitro toxin (tobacco) and studying its effects by transcriptomic analysis via high-throughput sequencing (NGS) at key steps during the model.
* Demonstrate the feasibility of obtaining iPS from peripheral blood sampling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients likely to develop COPD

Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).

Intervention: Bronchial biopsy

Intervention: Skin biopsy

Intervention: Blood sample

Bronchial biopsy

Intervention Type PROCEDURE

The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Skin biopsy

Intervention Type PROCEDURE

The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Blood sample

Intervention Type PROCEDURE

The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.

Patients not likely to develop COPD

Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).

Intervention: Bronchial biopsy

Intervention: Skin biopsy

Intervention: Blood sample

Bronchial biopsy

Intervention Type PROCEDURE

The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Skin biopsy

Intervention Type PROCEDURE

The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Blood sample

Intervention Type PROCEDURE

The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchial biopsy

The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Intervention Type PROCEDURE

Skin biopsy

The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Intervention Type PROCEDURE

Blood sample

The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has given his/her signed, informed consent
* Forced expiratory volume in 1 second / forced vital capacity \< 0.7 \[FEV1/FVC \< 0.7\]
* FEV1 \< 50% of predicted value
* Exclusion of other respiratory pathologies, based on anamnesis, computed tomography and complementary respiratory function tests and transthoracic ultrasound,
* Smoking \>10 pack-years, ongoing or weaned
* Absence of exacerbation or intercurrent infectious episode for at least 4 weeks at time of inclusion
* Medical indication for a bronchial fibroscopy (indication validated by the physician in charge of the patient and the study investigating physician): pulmonary peripheral nodule exploration with computed tomography, interventional endoscopy for emphysema reduction, removal of foreign bodies, other indications.
* Absence of contraindications for bronchial biopsy (left to physician's discretion): not limited to: regular intake of anticoagulants or anti-platelet aggregation, hemostasis abnormalities

* The patient has given his/her signed, informed consent
* Forced expiratory volume in 1 second / forced vital capacity \> 0.7 \[FEV1/FVC \> 0.7\]
* FEV1 \> 80% of predicted value
* Exclusion of other respiratory pathologies, based on anamnesis, computed tomography (absence of extensive emphysema lesions defined by the presence of less than \<5% relative surface area occupied by densities less than 910 UH (measured on millimeter cuts)) and respiratory function tests (Residual Volume \<120%, Diffusion Capacity for Carbon Monoxide \> 60% and Total Pulmonary Capacity\> 120%) and transthoracic ultrasound (normal),
* Smoking \>40 pack-years, ongoing or weaned
* Absence of exacerbation or intercurrent infectious episode for at least 4 weeks at time of inclusion
* Medical indication for a bronchial fibroscopy (indication validated by the physician in charge of the patient and the study investigating physician): pulmonary peripheral nodule exploration with computed tomography, interventional endoscopy for emphysema reduction, removal of foreign bodies, other indications.
* Absence of contraindications for bronchial biopsy (left to physician's discretion): not limited to: regular intake of anticoagulants or anti-platelet aggregation, hemostasis abnormalities

Exclusion Criteria

* Contra-indication for bronchial fibroscopy and cutaneous biopsy
* Deficiency in α-1 antitrypsin
* Significant bronchiectasis on chest computed tomography scan
* Colonization of the airways by Pseudomonas Aeroginosa or Aspergillus
* Chemotherapy or other cytotoxic treatments in the last 12 months
* Systemic corticotherapy in the 4 weeks prior to inclusion
* Long-term antibiotic treatment, notably by macrolides
* Any other treatment that may affect the bronchial epithelium, this being left to the discretion of the investigating physician
* Consumer of illicit drugs or alcohol
* Participant in an exclusion period determined by a previous study
* Subject not affiliated with, or not beneficiary of, a social security plan.
* Pregnant or nursing women according to Article L1121-5 of the Public Health Code.
* Vulnerable persons according to Article L1121-6 of the Public Health Code
* An adult who is protected or incapable of giving consent in accordance with Article L1121-8 of the Public Health Code
* Subject deprived of freedom by judicial or administrative decision.
* Those patients for whom two epithelia cultures (1 from bronchial biopsy ("ALI") and 1 from fibroblast reprogrammation of redifferentiated iPS ("iALI")) were not obtained will be excluded (post-inclusion).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No